OKYO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.620

Open

1.490

VWAP

1.52

Vol

108.39K

Mkt Cap

79.24M

Low

1.441

Amount

165.17K

EV/EBITDA(TTM)

--

Total Shares

52.48M

EV

74.87M

EV/OCF(TTM)

--

P/S(TTM)

--

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Show More

Events Timeline

(ET)

2026-03-18

07:20:00

OKYO Pharma Announces Positive Findings from Urcosimod Trial

2026-02-13 (ET)

2026-02-13

05:50:00

Piper Sandler Sets Deal Range at $1.80-$1.90

2026-02-12 (ET)

2026-02-12

16:10:00

Okyo Pharma Plans Underwritten Public Offering of Ordinary Shares

2026-02-10 (ET)

2026-02-10

08:20:00

OKYO Pharma Appoints Flavio Mantelli as Chief Medical Officer

2026-01-28 (ET)

2026-01-28

07:50:00

OKYO Pharma Holds Meeting with FDA, Confirms Urcosimod Clinical Trial Plan

2026-01-23 (ET)

2026-01-23

07:10:00

OKYO Pharma Receives FDA Approval for Expanded Use of Urgosimod

News

Newsfilter

02-23Newsfilter

OKYO Pharma to Present Urcosimod Data at ARVO 2026

Benzinga

Wall Street Analysts Adjust Ratings

NASDAQ.COM

02-13NASDAQ.COM

OKYO Pharma Prices Public Offering at $1.85 per Share

seekingalpha

02-13seekingalpha

OKYO Pharma Announces Public Offering of Shares

Newsfilter

02-13Newsfilter

OKYO Pharma Prices Public Offering at $1.85 per Share

Newsfilter

02-11Newsfilter

OKYO Pharma Transitions ATM Facility to Leerink Partners

2 Analyst Rating

Wall Street analysts forecast OKYO stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Piper Sandler

Biren Amin

Overweight

initiated

$7

AI Analysis

2026-02-20

Reason

Piper Sandler

Biren Amin

Price Target

$7

AI Analysis

2026-02-20

initiated

Overweight

Reason

Piper Sandler analyst Biren Amin initiated coverage of Okyo Pharma with an Overweight rating and $7 price target. The firm is positive on the company's lead asset, urcosimod, for the treatment of neuropathic corneal pain associated with either post-ocular surgery or dry eye disease. The Phase 2 data in both indications demonstrated a "meaningful" efficacy signal on pain endpoints while maintaining a "clean" safety profile, the analyst tells investors in a research note. Piper is "encouraged" by early data, saying the unmet need in neuropathic corneal pain is high as there are currently no approved treatments.

B. Riley

B. Riley

initiated

$5

2025-12-08

Reason

B. Riley

B. Riley

Price Target

$5

2025-12-08

initiated

Reason

B. Riley initiated coverage of Okyo Pharma with a Buy rating and $5 price target. The firm says the company is developing urcosimod, an anti-inflammatory, anti-pain approach to treat neuropathic corneal pain, a severe and debilitating eye condition. With no FDA-approved treatments, patients rely on off-label approaches, the analyst tells investors in a research note. Riley says its currently estimated 500,000 diagnosed patient pool could be much closer to 1M patients with improved diagnosis.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OKYO

Unlock Now

Valuation Metrics

The current forward P/E ratio for OKYO Pharma Ltd (OKYO.O) is -10.45, compared to its 5-year average forward P/E of -5.80. For a more detailed relative valuation and DCF analysis to assess OKYO Pharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.80

Current PE

-10.45

Overvalued PE

-1.90

Undervalued PE

-9.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.74

Undervalued EV/EBITDA

-5.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding OKYO

Trading Trends

People Also Watch

Frequently Asked Questions

What is OKYO Pharma Ltd (OKYO) stock price today?

The current price of OKYO is 1.51 USD — it has decreased -1.31

What is OKYO Pharma Ltd (OKYO)'s business?

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

What is the price predicton of OKYO Stock?

Wall Street analysts forecast OKYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKYO is6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is OKYO Pharma Ltd (OKYO)'s revenue for the last quarter?

OKYO Pharma Ltd revenue for the last quarter amounts to NaN USD, decreased

What is OKYO Pharma Ltd (OKYO)'s earnings per share (EPS) for the last quarter?

OKYO Pharma Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does OKYO Pharma Ltd (OKYO). have?

OKYO Pharma Ltd (OKYO) has 4 emplpoyees as of March 31 2026.

What is OKYO Pharma Ltd (OKYO) market cap?

Today OKYO has the market capitalization of 79.24M USD.